Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
Andres Forero-Torres*, Jeffrey R. Infante, David Waterhouse, Lucas Wong, Selwyn Vickers, Edward Arrowsmith, Aiwu Ruth He, Lowell Hart, David Trent, James Wade, Xiaoping Jin, Qiang Wang, Tashara Austin, Michael Rosen, Robert Beckman, Reinhard von Roemeling, Jonathan Greenberg, Mansoor Saleh
Dive into the research topics of 'Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer'. Together they form a unique fingerprint.